These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 30943868)

  • 1. Qualitative and Quantitative Analysis of IDH1 Mutation in Progressive Gliomas by Allele-Specific qPCR and Western Blot Analysis.
    Perrech M; Dreher L; Röhn G; Stavrinou P; Krischek B; Toliat M; Goldbrunner R; Timmer M
    Technol Cancer Res Treat; 2019 Jan; 18():1533033819828396. PubMed ID: 30943868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microfluidics for rapid detection of isocitrate dehydrogenase 1 mutation for intraoperative application.
    Aibaidula A; Zhao W; Wu JS; Chen H; Shi ZF; Zheng LL; Mao Y; Zhou LF; Sui GD
    J Neurosurg; 2016 Jun; 124(6):1611-8. PubMed ID: 26544771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression Profile Analysis of Zinc Transporters (ZIP4, ZIP9, ZIP11, ZnT9) in Gliomas and their Correlation with IDH1 Mutation Status.
    Kang X; Chen R; Zhang J; Li G; Dai PG; Chen C; Wang HJ
    Asian Pac J Cancer Prev; 2015; 16(8):3355-60. PubMed ID: 25921144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. cMYC expression in infiltrating gliomas: associations with IDH1 mutations, clinicopathologic features and outcome.
    Odia Y; Orr BA; Bell WR; Eberhart CG; Rodriguez FJ
    J Neurooncol; 2013 Nov; 115(2):249-59. PubMed ID: 23934175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isocitrate dehydrogenase 1 R132H mutation is not detected in angiocentric glioma.
    Raghunathan A; Olar A; Vogel H; Parker JR; Coventry SC; Debski R; Albarracin CT; Aldape KD; Cahill DP; Powell SZ; Fuller GN
    Ann Diagn Pathol; 2012 Aug; 16(4):255-9. PubMed ID: 22445362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomas.
    Chou AP; Chowdhury R; Li S; Chen W; Kim AJ; Piccioni DE; Selfridge JM; Mody RR; Chang S; Lalezari S; Lin J; Sanchez DE; Wilson RW; Garrett MC; Harry B; Mottahedeh J; Nghiemphu PL; Kornblum HI; Mischel PS; Prins RM; Yong WH; Cloughesy T; Nelson SF; Liau LM; Lai A
    J Natl Cancer Inst; 2012 Oct; 104(19):1458-69. PubMed ID: 22945948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Polymerase Chain Reaction-Restriction Fragment Length Polymorphism, Immunohistochemistry, and DNA Sequencing for the Detection of IDH1 Mutations in Gliomas.
    Malueka RG; Theresia E; Fitria F; Argo IW; Donurizki AD; Shaleh S; Innayah MR; Wicaksono AS; Dananjoyo K; Asmedi A; Hartanto RA; Dwianingsih EK
    Asian Pac J Cancer Prev; 2020 Nov; 21(11):3229-3234. PubMed ID: 33247679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of isocitrate dehydrogenase 1 mutation in 97 patients with glioma.
    Zhou YX; Wang JX; Feng M; Sun CM; Sun T; Chen GL; Du ZW
    J Mol Neurosci; 2012 Jul; 47(3):442-7. PubMed ID: 22113362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of immunohistochemistry, DNA sequencing and allele-specific PCR for the detection of IDH1 mutations in gliomas.
    Loussouarn D; Le Loupp AG; Frenel JS; Leclair F; Von Deimling A; Aumont M; Martin S; Campone M; Denis MG
    Int J Oncol; 2012 Jun; 40(6):2058-62. PubMed ID: 22447191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IDH1 status is significantly different between high-grade thalamic and superficial gliomas.
    Zuo M; Li M; Chen N; Yu T; Kong B; Liang R; Wang X; Mao Q; Liu Y
    Cancer Biomark; 2017 Aug; 20(2):183-189. PubMed ID: 28869450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
    Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A
    Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ZEB1 expression is increased in IDH1-mutant lower-grade gliomas.
    Nesvick CL; Zhang C; Edwards NA; Montgomery BK; Lee M; Yang C; Wang H; Zhu D; Heiss JD; Merrill MJ; Ray-Chaudhury A; Zhuang Z
    J Neurooncol; 2016 Oct; 130(1):111-122. PubMed ID: 27568035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors.
    Capper D; Weissert S; Balss J; Habel A; Meyer J; Jäger D; Ackermann U; Tessmer C; Korshunov A; Zentgraf H; Hartmann C; von Deimling A
    Brain Pathol; 2010 Jan; 20(1):245-54. PubMed ID: 19903171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endothelin B receptor expression in malignant gliomas: the perivascular immune escape mechanism of gliomas.
    Nakashima S; Sugita Y; Miyoshi H; Arakawa F; Muta H; Ishibashi Y; Niino D; Ohshima K; Terasaki M; Nakamura Y; Morioka M
    J Neurooncol; 2016 Mar; 127(1):23-32. PubMed ID: 26645886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel high-sensitivity assay to detect a small fraction of mutant IDH1 using droplet digital PCR.
    Hirano M; Ohka F; Maeda S; Chalise L; Yamamichi A; Aoki K; Kato A; Tanahashi K; Motomura K; Nishimura Y; Hara M; Shinjo K; Kondo Y; Wakabayashi T; Natsume A
    Brain Tumor Pathol; 2018 Apr; 35(2):97-105. PubMed ID: 29460200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of MGMT promoter methylation sites correlating with gene expression and IDH1 mutation in gliomas.
    Zhang J; Yang JH; Quan J; Kang X; Wang HJ; Dai PG
    Tumour Biol; 2016 Oct; 37(10):13571-13579. PubMed ID: 27468718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The diagnostic value of lower glucose consumption for IDH1 mutated gliomas on FDG-PET.
    Liu FM; Gao YF; Kong Y; Guan Y; Zhang J; Li SH; Ye D; Wen W; Zuo C; Hua W
    BMC Cancer; 2021 Jan; 21(1):83. PubMed ID: 33472598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative study of IDH1 mutations in gliomas by high resolution melting analysis, immunohistochemistry and direct DNA sequencing.
    Li J; Zhang H; Wang L; Yang C; Lai H; Zhang W; Chen X; Wang J
    Mol Med Rep; 2015 Sep; 12(3):4376-4381. PubMed ID: 26130305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An analysis of the prognostic value of IDH1 (isocitrate dehydrogenase 1) mutation in Polish glioma patients.
    Lewandowska MA; Furtak J; Szylberg T; Roszkowski K; Windorbska W; Rytlewska J; Jóźwicki W
    Mol Diagn Ther; 2014 Feb; 18(1):45-53. PubMed ID: 23934769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early experience with formalin-fixed paraffin-embedded (FFPE) based commercial clinical genomic profiling of gliomas-robust and informative with caveats.
    Movassaghi M; Shabihkhani M; Hojat SA; Williams RR; Chung LK; Im K; Lucey GM; Wei B; Mareninov S; Wang MW; Ng DW; Tashjian RS; Magaki S; Perez-Rosendahl M; Yang I; Khanlou N; Vinters HV; Liau LM; Nghiemphu PL; Lai A; Cloughesy TF; Yong WH
    Exp Mol Pathol; 2017 Aug; 103(1):87-93. PubMed ID: 28663030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.